THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Susanna Ulahannan to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications Susanna Ulahannan has written about Protein Kinase Inhibitors.
Susanna Ulahannan
Connection Strength
0.253
Protein Kinase Inhibitors
  1. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
    View in: PubMed
    Score: 0.167
  2. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 2011 May; 29(4):325-37.
    View in: PubMed
    Score: 0.085
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES